A 'More Radical Idea': Set Expiration Dates For Priority Review Vouchers
Sanofi executive offers five-year voucher life-span as potential option for sustaining the resale market.
You may also be interested in...
US incentive program would gain only four more years, despite calls for a permanent extension.
US FDA’s priority review voucher program delivers for most sponsors, a Pink Sheet analysis finds; PRVs reliably produce faster approval than priority-reviewed new drugs overall.
Sponsors will pay 12% less to redeem a voucher in FY 2020, which is charged on top of the traditional PDUFA user fee.